Sasank Nakka
Loma Linda University
3 Papers
Sasank Nakka is an academic researcher from Loma Linda University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study
Amit G. Singal,Nicole E. Rich,Neil Mehta,Andrea D. Branch,Anjana Pillai,Maarouf Hoteit,Michael L. Volk,Mobolaji Odewole,Steven J. Scaglione,Steven J. Scaglione,Jennifer Guy,Adnan Said,Jordan J. Feld,Binu John,Catherine Frenette,Parvez S. Mantry,Amol S. Rangnekar,Omobonike Oloruntoba,Michael D. Leise,Janice H. Jou,Kalyan Ram Bhamidimarri,Laura Kulik,Tram Tran,Hrishikesh Samant,Renumathy Dhanasekaran,Andres Duarte-Rojo,Reena Salgia,Sheila Eswaran,Prasun K. Jalal,Avegail Flores,Sanjaya K. Satapathy,Robert J. Wong,Annsa Huang,Suresh Misra,Myron Schwartz,Robert Mitrani,Sasank Nakka,Wassim Noureddine,Chanda Ho,Venkata Rajesh Konjeti,Alexander Dao,Kevin Nelson,Kelly Delarosa,Usman Rahim,Meher Sindhoora Mavuram,Jesse J. Xie,Caitlin C. Murphy,Neehar D. Parikh +47 more
TL;DR: In a large cohort of North American patients with complete response to HCC treatment, DAA therapy was not associated with increased overall or early HCC recurrence.
129
Wandering Gastric Leads: A Rare Complication of a New Treatment Modality of Gastroparesis
TL;DR: Despite the benefit of the GES, limited studies are commenting on the potential complications and the Gastric Electric Stimulator was made for refractory diabetic gastroparesis, defined by failure of 1 year of medical therapy.
Efficacy of Fecal Microbiota (REBYOTA) in Recurrent Clostridium difficile Infections: A Systematic Review and Meta-Analysis
Saivishnu Doosetty,Chukwuemeka A. Umeh,Wesley Eastwood,Isha Samreen,Ashwin Penchala,Harpreet Kaur,Christine Chilinga,Gagan Kaur,Tamanna Mohta,Sriharsha Nakka,Pavani Tangirala,Sasank Nakka +11 more
TL;DR: RBX2660 (REBYOTA) is effective in preventing recurrent Clostridium difficile infections.